{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:34:01Z","timestamp":1787582041522,"version":"build-2736575974"},"reference-count":22,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej18-0547","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T22:03:03Z","timestamp":1558735383000},"page":"701-708","source":"Crossref","is-referenced-by-count":16,"title":["Successful reduction of ACTH secretion in a case of intractable Cushing\u2019s disease with pituitary Crooke\u2019s cell adenoma by combined modality therapy including temozolomide"],"prefix":"10.1507","volume":"66","author":[{"given":"Sayuri","family":"Tanaka","sequence":"first","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Morita","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Takeno","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Kanazawa","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Endocrine Center, Division of Hypothalamic & Pituitary Surgery, Toranomon Hospital, Tokyo 105-8470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toranomon Hospital, Tokyo 105-8470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Oki","sequence":"additional","affiliation":[{"name":"Second Division Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Brain and Neurosciences, Faculty of Medicine Tottori University, Yonago 683-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, et al. (2003) Crooke\u2019s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27: 1330\u20131336.","DOI":"10.1097\/00000478-200310000-00005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, et al. (2009) High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing\u2019s disease. Eur J Endocrinol 161: 553\u2013559.","DOI":"10.1530\/EJE-09-0414"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Yamakita N, Murai T, Oki Y, Matsuhisa T, Hirata T, et al. (2001) Adrenal insufficiency after incomplete resection of pituitary macrocorticotropinoma of Cushing\u2019s disease: role of high molecular weight ACTH. Endocr J 48: 43\u201351.","DOI":"10.1507\/endocrj.48.43"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yonemura K, Yasuda H, Fujigaki Y, Oki Y, Hishida A (2003) Adrenal insufficiency due to isolated adrenocorticotropin deficiency complicated by autosomal recessive polycystic kidney disease. Ren Fail 25: 485\u2013492.","DOI":"10.1081\/JDI-120021162"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41: 1133\u20131148.","DOI":"10.1111\/j.1365-2362.2011.02520.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Oldfield EH, Vance ML, Louis RG, Pledger CL, Jane JA Jr, et al. (2015) Crooke\u2019s changes in Cushing\u2019s syndrome depends on degree of hypercortisolism and individual susceptibility. J Clin Endocrinol Metab 100: 3165\u20133171.","DOI":"10.1210\/JC.2015-2493"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, et al. (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178: G1\u2013G24.","DOI":"10.1530\/EJE-17-0796"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, et al. (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94: 4342\u20134350.","DOI":"10.1210\/jc.2009-1311"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146: 707\u2013716.","DOI":"10.1530\/eje.0.1460707"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7: 279\u2013289.","DOI":"10.1038\/nrendo.2011.12"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Wilson PJ, Williams JR, Smee RI (2014) Cushing\u2019s disease: a single centre\u2019s experience using the linear accelerator (LINAC) for stereotactic radiosurgery and fractionated stereotactic radiotherapy. J Clin Neurosci 21: 100\u2013106.","DOI":"10.1016\/j.jocn.2013.04.007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Starke RM, Williams BJ, Vance ML, Sheehan JP (2010) Radiation therapy and stereotactic radiosurgery for the treatment of Cushing\u2019s disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes 17: 356\u2013364.","DOI":"10.1097\/MED.0b013e32833ab069"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987\u2013996.","DOI":"10.1056\/NEJMoa043330"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997\u20131003.","DOI":"10.1056\/NEJMoa043331"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, et al. (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95: 4592\u20134599.","DOI":"10.1210\/jc.2010-0644"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Curt\u00f2 L, Torre ML, Ferra\u00f9 F, Pitini V, Altavilla G, et al. (2010) Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing\u2019s disease\u2014report of a case and literature review. Scientific World Journal 10: 2132\u20132138.","DOI":"10.1100\/tsw.2010.210"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, et al. (2009) Treatment of Nelson\u2019s syndrome with temozolomide. Eur J Endocrinol 160: 115\u2013119.","DOI":"10.1530\/EJE-08-0557"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64: E773\u2013E774.","DOI":"10.1227\/01.NEU.0000339115.12803.4E"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Asimakopoulou A, Tzanela M, Koletti A, Kontogeorgos G, Tsagarakis S (2014) Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide. Clin Case Rep 2: 1\u20133.","DOI":"10.1002\/ccr3.39"},{"key":"20","doi-asserted-by":"crossref","unstructured":"22 Momota H, Narita Y, Miyakita Y, Shibui S (2013) Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 15: 1445\u20131450.","DOI":"10.1093\/neuonc\/not036"},{"key":"21","doi-asserted-by":"crossref","unstructured":"23 Kosugi K, Saito K, Takahashi W, Tokuda Y, Tomita H (2017) A case of therapy-related acute myeloid leukemia associated with adjuvant temozolomide chemotherapy for anaplastic astrocytoma. World Neurosurg 101: 816.e11\u2013816.e16.","DOI":"10.1016\/j.wneu.2017.02.068"},{"key":"22","doi-asserted-by":"crossref","unstructured":"24 Campder\u00e1 M, Palacios N, Aller J, Magall\u00f3n R, Mart\u00edn P, et al. (2016) Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. Pituitary 19: 158\u2013166.","DOI":"10.1007\/s11102-015-0694-x"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/8\/66_EJ18-0547\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T03:42:55Z","timestamp":1567222975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/8\/66_EJ18-0547\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0547","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}